JNJ Acquires Firefly Bio
JNJ acquires Firefly Bio to advance oncology innovation
JNJ - earlier PR: Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation -Broadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers -Adds novel degrader antibody conjugate platform designed to address key limitations of existing Therapies -Advances leadership in next-generation antibody engineering to accelerate Oncology innovation